Other languages Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Market Closed - OTC Markets Other stock markets 03:35:44 2024-05-31 pm EDT			5-day change	1st Jan Change
0.0355 ^USD	-.--%		-11.25%	-64.50%

Mar. 22	Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
2023	Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 22
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	Dec. 27
Odyssey Health, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 15
Odyssey Health, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-30
Odyssey Health, Inc. Announces the Resignation of John Gandolfo as Director	23-10-06
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate	23-10-06
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04
Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS	23-08-23
AM Best Upgrades Credit Ratings of Odyssey Group Holdings, Inc.'s Members	23-07-07
Odyssey Health, Inc. executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.	23-06-27
Odyssey Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14
ODYSSEY HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	23-04-04
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment	23-03-30
ODYSSEY HEALTH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-03-17
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17
Odyssey Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-17
Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research	23-02-07
ODYSSEY HEALTH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-01-13
Odyssey Health, Inc. Appoints Jeffrey Conroy as Director	23-01-13
Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote	23-01-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Odyssey Health, Inc.

Equities

ODYY

US67612C1027

Other languages

Filters